Novartis UK Selects Captiva's InputAccel for Invoices; Company to Streamline Invoice Processing, Speed Payments to Suppliers
2005年6月14日 - 8:30PM
ビジネスワイヤ(英語)
Captiva Software Corporation (NASDAQ:CPTV), a leading provider of
input management solutions, today announced that Novartis UK, the
British affiliate of Novartis AG, a world leader in the research
and development of products to protect and improve health and well
being, has selected Captiva's InputAccel for Invoices(TM) to
capture and process invoices more efficiently and speed payment to
suppliers. InputAccel for Invoices' intelligent document
recognition and line-item capture capabilities enable Novartis to
accurately and efficiently process its often complex invoices
without the need to create templates for each supplier. After
capturing the pertinent data, InputAccel for Invoices exports
invoice information and images into the company's SAP financial
system for streamlined processing, storage and retrieval. Novartis
selected InputAccel for Invoices in part because of its SAP
certification, ensuring seamless integration with the company's
legacy accounting system. In addition, Novartis chose the solution
because it is built on InputAccel(R), Captiva's award-winning
document capture software, which Novartis is considering for use in
other departments throughout the company to capture clinical trial,
customer service and human resources documents. "Novartis desired
an automated invoice capture solution that is flexible enough to
grow with the company's future needs," said Daniel Vaniche,
Captiva's Vice President of Field Sales and Operations in Europe,
Middle East and Africa (EMEA). "We're pleased to provide a solution
that not only meets Novartis' current needs, but is also scalable
enough to meet the company's future needs as it expands document
capture to its other business units." Built on InputAccel and
utilizing capabilities from FormWare(R), InputAccel for Invoices
enables companies to process invoices more efficiently and
accurately, reduce turnaround times for payment, take advantage of
early payment discounts and to easily access captured invoice
images and electronic data. About Novartis UK Novartis UK is the
British affiliate of Novartis AG. Headquartered in Basel,
Switzerland, Novartis AG is a world leader in pharmaceuticals and
consumer health. Last year, the Group's businesses achieved sales
of $28.2 billion (US), net income of $5.8 billion (US) and invested
approximately $4.2 billion (US) in research and development.
Novartis Group companies employ more than 80,000 people and operate
in over 140 countries around the world. Further information about
Novartis UK is available at www.novartis.co.uk. About Captiva
Software Corporation Captiva Software Corporation (NASDAQ:CPTV) is
a leading provider of input management software solutions. Since
1989, the company's award-winning products have been used to manage
business critical information from paper, faxed and scanned forms
and documents, Internet forms and XML data streams into the
enterprise in a more accurate, timely and cost-effective manner.
These products automate the processing of billions of forms and
documents annually, converting their contents into information that
is usable in database, document, content and other information
management systems. Captiva's technology serves thousands of users
in insurance, financial services, government, business process
outsourcing, direct marketing and other markets. For more
information, visit www.captivasoftware.com. InputAccel for Invoices
is a trademark, and InputAccel and FormWare are registered
trademarks of Captiva Software Corporation. All other trademarks or
registered trademarks are the property of their respective owners.
This press release may contain forward-looking statements that
involve risks and uncertainties, as well as assumptions that, if
they prove incorrect, could cause our results to differ materially
from those expressed or implied by such forward-looking statements.
All statements other than statements of historical fact are
statements that could be deemed forward-looking statements,
including, among other things, any projections of earnings,
revenues (including where the underlying contract has already been
signed), or other financial items; any statements of the plans,
strategies, and objectives of management for future operations; any
statements concerning proposed new products, services, or
developments; any statements regarding future economic conditions
or performance; statements of belief and any statement of
assumptions underlying any of the foregoing. The risks,
uncertainties and assumptions referred to above include, among
other things, performance of contracts by customers and partners;
employee management issues; the timely development, production and
acceptance of products and services and their feature sets; the
challenge of managing asset levels, including inventory; the flow
of products into third-party distribution channels; and the
difficulty of keeping expense growth at modest levels while
increasing revenues. Announcements of contract awards should not be
interpreted as reflecting revenue in any particular period and may
relate to revenue recorded in prior periods. These and other risks
and factors that could cause events or our results to differ from
those expressed or implied by such forward-looking statements are
described in our most recent annual report on Form 10-K and
quarterly reports on Form 10-Q, as well as other subsequent filings
with the Securities and Exchange Commission. We assume no
obligation and do not intend to update these forward-looking
statements.
Captiva (NASDAQ:CPTV)
過去 株価チャート
から 5 2024 まで 6 2024
Captiva (NASDAQ:CPTV)
過去 株価チャート
から 6 2023 まで 6 2024